Starling Oncology, Inc. STLN
3.40 USD -0.14 (-3.95%)
Regular-session close
3.40 0.00 0.00%
After hours · Nov 17, 4:07 PM ET
3.36 Day range 3.67
2.38 52-week range 7.05
- YTD
- -4.49%
- 1 year
- -9.81%
News
seekingalpha.com Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcriptbenzinga.com B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10 B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.
marketbeat.com Oncology Institute Q3 Earnings Call Highlights Oncology Institute NASDAQ: STLN, referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…benzinga.com BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10 BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.
zacks.com Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates Starling Oncology, Inc. (STLN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
benzinga.com Starling Oncology Q3 2026 Earnings Call Transcript Starling Oncology (NASDAQ:STLN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est Starling Oncology (NASDAQ:STLN) narrows FY2026 sales outlook from $650.000 million-$670.000 million to $650.000 million-$660.000 million vs $663.685 million estimate.
benzinga.com Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of…
globenewswire.com Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States,…
globenewswire.com Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its…
defenseworld.net Oncology Institute (NASDAQ:STLN) Shares Climb 6.1% – Should You Buy? Shares of Oncology Institute, Inc. (NASDAQ: STLN - Get Free Report) were up 6.1% on Friday. The stock traded as high as $6.56 and last traded at $6.56. Approximately 133,504 shares changed hands…
seekingalpha.com Cedar Grove Capital Q3 2026 Portfolio Update During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican…
globenewswire.com Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders…
seekingalpha.com Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating Starling Oncology is rated BUY, supported by strong secular growth and expanding adoption of its oncology managed care services. STLN's revenue model leverages scalable delegation contracts, driving…
globenewswire.com Starling Oncology to Participate in Wells Fargo Healthcare Conference CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States,…
globenewswire.com Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States,…
seekingalpha.com Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
zacks.com The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
globenewswire.com Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States,…
